Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

被引：0
|
作者：
Takayuki Ueno
Shigehisa Kitano
Norikazu Masuda
Daiki Ikarashi
Makiko Yamashita
Tomohiro Chiba
Takayuki Kadoya
Hiroko Bando
Takashi Yamanaka
Shoichiro Ohtani
Shigenori Nagai
Takahiro Nakayama
Masato Takahashi
Shigehira Saji
Kenjiro Aogi
Ravi Velaga
Kosuke Kawaguchi
Satoshi Morita
Hironori Haga
Shinji Ohno
Masakazu Toi
机构：
[1] The Cancer Institute Hospital of JFCR,Breast Surgical Oncology
[2] The Cancer Institute Hospital of JFCR,Division of Cancer Genomic Medicine Development, Advanced Medical Development Center
[3] The Cancer Institute Hospital of JFCR,Division of Cancer Immunotherapy Development, Advanced Medical Development Center
[4] Nagoya University Graduate School of Medicine,Department of Breast and Endocrine Surgery
[5] The Cancer Institute Hospital of JFCR,Division of Pathology
[6] Hiroshima University Hospital,Department of Breast Surgery
[7] Hiroshima University,Breast and Endocrine Surgery, Faculty of Medicine
[8] University of Tsukuba,Department of Breast and Endocrine Surgery
[9] Kanagawa Cancer Center,Department of Breast Surgery
[10] Hiroshima City Hiroshima Citizens Hospital,Division of Breast Oncology
[11] Saitama Cancer Center,Department of Breast and Endocrine Surgery
[12] Osaka International Cancer Institute,Department of Breast Surgery
[13] NHO Hokkaido Cancer Center,Department of Medical Oncology
[14] Fukushima Medical University Hospital,Department of Breast Oncology
[15] National Hospital Organization Shikoku Cancer Center,Department of Breast Surgery
[16] Kyoto University Hospital,Department of Biomedical Statistics and Bioinformatics
[17] Kyoto University Graduate School of Medicine,Department of Diagnostic Pathology
[18] Kyoto University Hospital,Breast Oncology Center
[19] The Cancer Institute Hospital of JFCR,Department of Breast Surgery
[20] Kyoto University Graduate School of Medicine,undefined
来源：
BMC Medicine | / 20卷
关键词：
Triple-negative breast cancer; Homologous recombination deficiency (HRD); Immune microenvironment; Neoadjuvant chemotherapy; Platinum; Eribulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
    Ueno, Takayuki
    Kitano, Shigehisa
    Masuda, Norikazu
    Ikarashi, Daiki
    Yamashita, Makiko
    Chiba, Tomohiro
    Kadoya, Takayuki
    Bando, Hiroko
    Yamanaka, Takashi
    Ohtani, Shoichiro
    Nagai, Shigenori
    Nakayama, Takahiro
    Takahashi, Masato
    Saji, Shigehira
    Aogi, Kenjiro
    Velaga, Ravi
    Kawaguchi, Kosuke
    Morita, Satoshi
    Haga, Hironori
    Ohno, Shinji
    Toi, Masakazu
    [J]. BMC MEDICINE, 2022, 20 (01)
  • [2] Immune microenvironment, homologous recombination deficiency and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: JBCRG22 TR
    Ueno, T.
    Kitano, S.
    Masuda, N.
    Ikarashi, D.
    Yamashita, M.
    Kadoya, T.
    Bando, H.
    Yamanaka, T.
    Ohtani, S.
    Nagai, S.
    Nakayama, T.
    Takahashi, M.
    Saji, S.
    Aogi, K.
    Velaga, R. M.
    Kawaguchi, K.
    Morita, S.
    Haga, H.
    Ohno, S.
    Toi, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1217 - S1218
  • [3] Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22)
    Bando, H.
    Masuda, N.
    Yamanaka, T.
    Kadoya, T.
    Takahashi, M.
    Nagai, S.
    Ohtani, S.
    Aruga, T.
    Suzuki, E.
    Kikawa, Y.
    Yasojima, H.
    Kasai, H.
    Ishiguro, H.
    Kawabata, H.
    Morita, S.
    Haga, H.
    Kataoka, T. R.
    Uozumi, R.
    Ohno, S.
    Toi, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S305 - S306
  • [4] Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
    Telli, Melinda L.
    Timms, Kirsten M.
    Reid, Julia
    Hennessy, Bryan
    Mills, Gordon B.
    Jensen, Kristin C.
    Szallasi, Zoltan
    Barry, William T.
    Winer, Eric P.
    Tung, NadineM.
    Isakoff, Steven J.
    Ryan, Paula D.
    Greene-Colozzi, April
    Gutin, Alexander
    Sangale, Zaina
    Iliev, Diana
    Neff, Chris
    Abkevich, Victor
    Jones, Joshua T.
    Lanchbury, Jerry S.
    Hartman, Anne-Renee
    Garber, Judy E.
    Ford, James M.
    Silver, Daniel P.
    Richardson, Andrea L.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3764 - 3773
  • [5] Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency
    Stecklein, Shane R.
    Barlow, William
    Pusztai, Lajos
    Timms, Kirsten
    Kennedy, Richard
    Logan, Gemma E.
    Seitz, Rob
    Badve, Sunil
    Gokmen-Polar, Yesim
    Porter, Peggy
    Linden, Hannah
    Tripathy, Debu
    Hortobagyi, Gabriel N.
    Godwin, Andrew K.
    Thompson, Alastair
    Hayes, Daniel F.
    Sharma, Priyanka
    [J]. JCO PRECISION ONCOLOGY, 2023, 7
  • [6] Homologous recombination deficiency in triple negative breast cancer
    Belli, Carmen
    Duso, Bruno Achutti
    Ferraro, Emanuela
    Curigliano, Giuseppe
    [J]. BREAST, 2019, 45 : 15 - 21
  • [7] Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer
    Richardson, Andrea L.
    Silver, Daniel P.
    Szallasi, Zoltan
    Birkbak, Nicolai J.
    Wang, Zhigang C.
    Iglehart, J. Dirk
    Mayer, Erica L.
    Winer, Eric P.
    Tung, Nadine M.
    Ryan, Paula D.
    Isakoff, Steven J.
    Barry, William T.
    Greene-Collozi, April
    Gutin, Alexander
    Reid, Julia
    Neff, Chris
    Jones, Joshua
    Timms, Kirsten
    Hartman, Anne-Renee
    Garber, Judy E.
    [J]. CANCER RESEARCH, 2015, 75
  • [8] Effect of tumor microenvironment on chemotherapy response of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy
    Kim, Jae-Joon
    Kim, Dongjin
    Yu, Yeuni
    Jung, Ki Sun
    Kim, Yun Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Indicators of Homologous Recombination Deficiency in Breast Cancer and Association with Response to Neoadjuvant Chemotherapy
    Lips, E. H.
    Mulder, L.
    Hannemann, J.
    Laddach, N.
    Vrancken-Peeters, M-J F. T. D.
    van de Vijver, M. J.
    Wesseling, J.
    Nederlof, P. M.
    Rodenhuis, S.
    [J]. CANCER RESEARCH, 2010, 70
  • [10] Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy
    Lips, E. H.
    Mulder, L.
    Hannemann, J.
    Laddach, N.
    Peeters, M. T. F. D. Vrancken
    van de Vijver, M. J.
    Wesseling, J.
    Nederlof, P. M.
    Rodenhuis, S.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (04) : 870 - 876
12345